Vosoritide in achondroplasia: indication of an additional clinical benefit for children aged two and over

1 December 2023 - Two small RCTs with children of different ages together make it possible to make one statement: the ...

Read more →

Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project

28 January 2022 - This article aims at describing the most relevant elements of the drug development process in the paediatric ...

Read more →

Immunotherapy with blinatumomab improves the chances of survival in very rare childhood blood cancer

20 January 2022 - The Federal Joint Committee (G-BA) today classified the additional benefit of the active ingredient blinatumomab as significant ...

Read more →

Secukinumab in children with plaque psoriasis: study unsuitable for benefit assessment

3 December 2020 - Inappropriate treatment in the control arm makes fair comparison impossible. ...

Read more →

Asfotase alfa in hypophosphatasia in children and adolescents: survival advantage for small children

15 January 2020 - Weak evidence does not allow a specific statement to be made about the extent of the added ...

Read more →

A breakthrough cancer drug has been approved. Now comes the battle over the price.

12 Septemner 2018 - Novartis' breakthrough cancer drug Kymriah has been approved in Europe. Now comes the debate about its ...

Read more →

HIV-positive children and adolescents: additional benefit of rilpivirine not proven

1 April 2016 - Under the trade name Edurant, rilpivirine hydrochloride as single agent has been approved already since 2011 for ...

Read more →